Previous close | 23.86 |
Open | 24.14 |
Bid | 24.01 x 100 |
Ask | 24.07 x 600 |
Day's range | 23.92 - 24.48 |
52-week range | 22.01 - 33.71 |
Volume | |
Avg. volume | 2,098,056 |
Market cap | 4.07B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 7.16 |
EPS (TTM) | 3.36 |
Earnings date | 22 Jul 2024 - 26 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 34.45 |
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.